Location History:
- Moncalieri, IT (2016)
- Turin, IT (2016 - 2022)
Company Filing History:
Years Active: 2016-2022
Title: Benedetta Bussolati: Innovator in Renal Cancer Treatment
Introduction
Benedetta Bussolati is a prominent inventor based in Turin, Italy. She has made significant contributions to the field of regenerative medicine, particularly in the treatment of renal cancer. With a total of 3 patents, her work focuses on innovative pharmaceutical carriers and stem cell therapies.
Latest Patents
Bussolati's latest patents include groundbreaking methods for treating renal cancer. One notable invention involves pharmaceutical carriers containing microRNAs (miRNAs) for use in renal cancer treatment. This method utilizes a pharmaceutically acceptable carrier comprising specific miRNAs, including miR-15a, miR-181b, miR-320c, and miR-874. The carrier is designed as an extracellular vesicle derived from adult stem cells, such as mesenchymal stem cells (MSC), non-oval human liver progenitor cells (HLSC), and adipose stem cells (ASC). Another significant patent pertains to isolated multipotent mesenchymal stem cells derived from adult human kidneys. This invention focuses on a specific marker profile and outlines methods for preparing these cells for regenerative treatments targeting kidney injuries or diseases.
Career Highlights
Throughout her career, Benedetta Bussolati has worked with notable companies, including Fresenius Medical Care Deutschland GmbH and Unicyte Ev AG. Her expertise in regenerative medicine and innovative therapies has positioned her as a leader in her field.
Collaborations
Bussolati has collaborated with esteemed colleagues, including Giovanni Camussi and Maria Beatriz Herrera Sanchez. These partnerships have further enhanced her research and development efforts in the medical field.
Conclusion
Benedetta Bussolati's contributions to renal cancer treatment and regenerative medicine highlight her innovative spirit and dedication to improving patient outcomes. Her patents and collaborations reflect her commitment to advancing medical science and technology.